← Leaderboards
Kevin J. Frankowski
Univ Of North Carolina Chapel Hill
$2,124,533
Attributed
$3,393,816
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,393,816 · 3
By mechanism
R01$2,538,566 · 1
R21$427,625 · 1
UG3$427,625 · 1
Top collaborators
- Sui Huang4 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Andrea G Nackley$13,815,478
- Gabriel S Dichter$6,258,364
- David S Lalush$1,509,265
- Crystal Edler Schiller$2,016,804
- Jen Jen Yeh$14,819,320
Others in their field
Other Emerging Leaders on “Experimental Study”
- John Hobbs · Suny At Stony Brook$42,194,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$41,527,040
- Christopher Bee · Suny At Stony Brook$41,239,084
- Lynn Briscoe · Leidos Biomedical Research, Inc.$24,024,342
- John Damon Chodera · Sloan-Kettering Inst Can Research$18,835,102
- Alan D. Palkowitz · Indiana University Indianapolis$17,630,798
Research focus
Experimental StudyNovel TherapeuticsEvaluationDrug KineticsPropertyAnalogIn VivoHigh Throughput ScreeningIn VitroBindingScaffoldUnited States National Institutes Of HealthSmall MoleculeStructureLibrariesPathway InteractionsAnimalsExhibitsDrug DevelopmentEffective TherapyPre-ClinicalAreaCarcinogenesisAntineoplastic Agents
Grant awards (8)
Phenotypic marker-guided development of selective antimetastasis therapeutic leads$641,429
R01 · FY2025 · CA
Phenotypic marker-guided development of selective antimetastasis therapeutic leads$609,809
R01 · FY2024 · CA
Phenotypic marker-guided development of selective antimetastasis therapeutic leads$629,518
R01 · FY2023 · CA
Phenotypic marker-guided development of selective antimetastasis therapeutic leads$657,810
R01 · FY2022 · CA
D1 dopamine receptor positive allosteric modulators as a practical treatment for cognitive decline$233,250
R21 · FY2022 · AG · contact PI
Negative allosteric modulators of the D3 dopamine receptor as therapeutic leads for substance use disorders$194,375
UG3 · FY2022 · DA · contact PI
Negative allosteric modulators of the D3 dopamine receptor as therapeutic leads for substance use disorders$233,250
UG3 · FY2021 · DA · contact PI
D1 dopamine receptor positive allosteric modulators as a practical treatment for cognitive decline$194,375
R21 · FY2021 · AG · contact PI